Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Zehngebot

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
American Journal of Otolaryngology|August 1, 1980
Chemotherapy for squamous cell carcinoma of the head and neck: a progress reportJ H Glick, L M Zehngebot, S G Taylor
Cancer Immunology, Immunotherapy : CII|January 1, 1983
Functional consequence of variation in melanoma antigen expressionL M Zehngebot, M A Alexander, D Guerry, et al.
The Journal of Clinical Investigation|January 1, 1984
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytesD Guerry, M A Alexander, M F Herlyn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2009
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)M A Socinski, M N Saleh, D F Trent, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
American Journal of Otolaryngology|August 1, 1980
Chemotherapy for squamous cell carcinoma of the head and neck: a progress reportJ H Glick, L M Zehngebot, S G Taylor
Cancer Immunology, Immunotherapy : CII|January 1, 1983
Functional consequence of variation in melanoma antigen expressionL M Zehngebot, M A Alexander, D Guerry, et al.
The Journal of Clinical Investigation|January 1, 1984
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytesD Guerry, M A Alexander, M F Herlyn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2009
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)M A Socinski, M N Saleh, D F Trent, et al.
Cancer|May 4, 2001
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case studyI Cokgor, G Akabani, H S Friedman, et al.
Pageof 1